Navigation Links
Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
Date:5/12/2011

SAN DIEGO, May 12, 2011 /PRNewswire/ --  Naviscan, Inc., the leader in 3D Molecular Breast Imaging (MBI), has entered into a distribution agreement with Chindex Medical Limited to market and service Naviscan's high-resolution organ-specific PET scanner in the People's Republic of China, including Hong Kong and Macau.  The agreement represents the introduction of PEM (Positron Emission Mammography), the scanner's breast application, as a new tool available to Chinese women in their fight against breast cancer.

Naviscan manufactures the only commercially-available PEM scanner and PEM-guided biopsy system.  The scanner uses PET technology to produce tomographic images that allow physicians to visualize and biopsy breast tumors as small as 1.3 mm, the width of a grain of rice.  In recently published data, PEM has been found to be significantly more precise at identifying benign and cancerous lesions, in what scientists call "specificity", therefore reducing the number of unnecessary biopsies.  This finding is a welcomed outcome for women and physicians looking for ways to reduce the patient trauma and cost associated with unnecessary procedures.  

Chindex Medical Limited is a specialized full-service distributor of high tech medical equipment in Greater China, including a strong presence in the minimally-invasive surgical and imaging sectors as the exclusive distributor for the Intuitive Surgical daVinci® Surgical Systems, and Siemens high-end ultrasound and Hologic mammography products.  The Naviscan PET scanner is an ideal complement to Chindex Medical Limited's breast and surgery expertise and an ideal partner to continue its expansion in Asia.  

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com

About Chindex Medical Limited

Chindex Medical Limited is a joint venture between Fosun Pharma and Chindex International, Inc. with manufacturing and distribution businesses serving both domestic China and export markets.  Combining Chindex's more than thirty years of experience as a leading provider of capital equipment in China with FosunPharma's development over the past fifteen years as the largest private medical and pharmaceutical enterprise in China, the Company's vision is to become a global leader in the healthcare market.  Additional information can be found at http://www.chindex.com/cml/index.html


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
2. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
3. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
4. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
5. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
6. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
7. Naviscan Announces European Launch of Positron Emission Mammography
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... 9, 2016  Insulet Corporation (NASDAQ: PODD ) (Insulet ... technology with its OmniPod ® Insulin ... has been appointed to Insulet,s Board of Directors. With his ... of whom are independent. --> ... and finance experience and a deep knowledge of accounting, financial ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... It’s that time of year when most people have forgotten all about their New ... (IAAM), Hall of Fame athlete and Garrison Forest School athletic director since 2005, knows ... of her first decisions when her IAAM two-year presidency began last July was to ...
(Date:2/9/2016)... Albuquerque, NM (PRWEB) , ... February 09, 2016 , ... ... proceeds from its Heart Rate Variability scans throughout the month to the American Heart ... to spot the first signs of heart disease and Health Quest’s INSiGHT Pulse Wave ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... Snowfall4pod Digital, creators of the gContentManager & Distribution Network, today announced the ... and print-on-demand network. , AVALANCHE allows enterprise customers to license and create ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research ... playing field .” , As corresponding author Dr John F. Peppin says “Terminology matters, ... diagnose our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are ...
(Date:2/9/2016)... ... 2016 , ... METTLER TOLEDO has published a new guide ... understanding of the techniques they use so they can more easily spot potential ... and rework to create a leaner overall lab experience. , The new ...
Breaking Medicine News(10 mins):